[大脑的成年人如何治疗]
Anne Christina Rasmussen1, Jørgen Feldbæk Nielsen1,2, Jens Bo Nielsen3,4
1Hammel Neurorehabilitation Centre and University Research Clinic (HNURC).
Ugeskrift for laeger
|March 24, 2025
概括
丹麦缺乏专门的公共服务,用于大脑 (CP) 的成年人. 本综述提出了一种临床资格化模型,以改善患有CP的个体的复杂护理,解决多病症和功能衰退问题.
科学领域:
- 神经学 神经学
- 康复医学 康复医学 康复医学
- 公共卫生政策 公共卫生政策
背景情况:
- 大人脑 (CP) 面临复杂的医疗保健需求.
- 丹麦目前的治疗缺乏专门的,由税收资助的服务.
- 现有的护理涉及多个社会和医疗保健系统.
研究的目的:
- 审查丹麦CP成年人目前的治疗状况.
- 为系统化护理提出临床康复模式.
- 为CP管理激发跨医学专业的临床推理.
主要方法:
- 对当前治疗实践的文献综述.
- 对医疗保健和社会服务参与的分析.
- 拟议的临床资格化模型的开发.
主要成果:
- 丹麦没有专门的公共,税收资助的专业服务,用于患有CP的成年人.
- 复杂性包括大脑发育障碍,多病症和功能衰退.
- 提出了一个逐步的临床资格化模型.
结论:
- 需要一个结构化的habilitation模型来优化CP的成年人的护理.
- 拟议的模型旨在加强临床推理和跨学科合作.
- 系统化的护理可以满足这一群体的多方面的需求.
相关概念视频
Parkinson's Disease: Treatment
166
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
166
Alzheimer's Disease: Treatment
137
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
137
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
123
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
123


